Interestingly, rolipram, a PDE4 inhibitor, has been shown to improve cognitive function, as well as depression- and anxiety-like behavior in transgenic mouse models of AD, possibly by inhibiting apoptosis, amyloid pathology, tau phosphorylation and neuroinflammation [125]. Here, MAPT is linked to Alzheimer disease.